Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> signed a contract manufacturing agreement worth KRW1.7T ($1.2B) with an Asian pharmaceutical company. <a href="https://www.smartkarma.com/entities/celltrion-inc" target="_blank" data-smartkarma-citation="entities:991:1" rel="noopener">Celltrion Inc (068270 KS)</a> has announced KRW100B ($72M) share buyback, starting October 28.</li>
<li>
<a href="https://www.smartkarma.com/entities/astellas-pharma-inc" target="_blank" data-smartkarma-citation="entities:6091:1" rel="noopener">Astellas Pharma (4503 JP)</a> received FDA approval for Vyloy for gastric cancer. <a href="https://www.smartkarma.com/entities/shionogi-co-ltd" target="_blank" data-smartkarma-citation="entities:19535:1" rel="noopener">Shionogi &amp; Co (4507 JP)</a> received FDA Fast Track designation for its RSV drug candidate, S-337395.</li>
<li>
<a href="https://www.smartkarma.com/entities/zai-lab-ltd-94df40cf-c15e-462f-b3de-8d2d434ae935" target="_blank" data-smartkarma-citation="entities:36261:1" rel="noopener">Zai Lab (9688 HK)</a> announced positive topline data from global Phase 1a/1b study of ZL-1310 in small cell lung cancer. <a href="https://www.smartkarma.com/entities/legend-biotech-corp" target="_blank" data-smartkarma-citation="entities:28963:1" rel="noopener">Legend Biotech Corp (LEGN US)</a> sheds Genscript Biotech as its majority shareholder.</li>
</ul>



Samsung Biologics (207940 KS) signed a contract manufacturing agreement worth KRW1.7T ($1.2B) with an Asian pharmaceutical company. Celltrion Inc (068270 KS) has announced KRW100B ($72M) share buyback, starting October 28.

Astellas Pharma (4503 JP) received FDA approval for Vyloy for gastric cancer. Shionogi &amp; Co (4507 JP) received FDA Fast Track designation for its RSV drug candidate, S-337395.

Zai Lab (9688 HK) announced positive topline data from global Phase 1a/1b study of ZL-1310 in small cell lung cancer. Legend Biotech Corp (LEGN US) sheds Genscript Biotech as its majority shareholder.


APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

<ul>
<li>NIO: NIO to offer single-motor model in sub-brand codenamed Alps (+)</li>
<li>BEKE: Political Bureau of the Central Committee shifted tone on real estate regulation（+）</li>
<li>LEGN: Janssen reported CARVYKTI sales US$117mn, lower than our expectation (-)</li>
</ul>


NIO: NIO to offer single-motor model in sub-brand codenamed Alps (+)
BEKE: Political Bureau of the Central Committee shifted tone on real estate regulation（+）
LEGN: Janssen reported CARVYKTI sales US$117mn, lower than our expectation (-)


China TMT Update-NIO/BEKE/LEGN-NIO to Offer Single-Motor Model;Political Bureau Shifted Tone

Healthcare Analyst

Wilfred Yuen

Equity Bottom-Up

<ul>
<li>
1H26 results driven by AI orders, with life sciences segment revenue up 26% YoY (or +16% HoH) and adjusted operating profit up 103% YoY to US$94m.</li>
<li>
2026 guidance upgrade: 1) Life science: 25-30% revenue growth (vs. 15-18% prior), with adjusted OPM: 25%+ (vs. 19% prior); 2) Probio: 25-30% fee-for-service revenue growth (vs. 20-25% prior)</li>
<li>
At US$7.2bn mkt cap (vs. TWST: US$7.4bn), our back-of-envelop calculation indicates ~36x 2027E P/E. Genscript holds net cash of US$638m and 45% stake in LEGN. See inside for call takeaways</li>
</ul>



1H26 results driven by AI orders, with life sciences segment revenue up 26% YoY (or +16% HoH) and adjusted operating profit up 103% YoY to US$94m.

2026 guidance upgrade: 1) Life science: 25-30% revenue growth (vs. 15-18% prior), with adjusted OPM: 25%+ (vs. 19% prior); 2) Probio: 25-30% fee-for-service revenue growth (vs. 20-25% prior)

At US$7.2bn mkt cap (vs. TWST: US$7.4bn), our back-of-envelop calculation indicates ~36x 2027E P/E. Genscript holds net cash of US$638m and 45% stake in LEGN. See inside for call takeaways


Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio

<ul>
<li>2252HK:   NHC issued the "14th Five-Year Plan for Large-Scale Medical Equipment Allocation" ,  the planned quota of laparoscopic robots is slightly lower than our estimated (-)</li>
<li>1801HK/LEGN:Innovent/ISAO co-developed CAR-T received approval in China ahead   of Legend’s CARVIKTI, might try to squeeze in NDRL list this year (+)</li>
<li>LKNCY: Luckin Coffee reported 50mn monthly transacting customers in June(/)</li>
</ul>


2252HK:   NHC issued the "14th Five-Year Plan for Large-Scale Medical Equipment Allocation" ,  the planned quota of laparoscopic robots is slightly lower than our estimated (-)
1801HK/LEGN:Innovent/ISAO co-developed CAR-T received approval in China ahead   of Legend’s CARVIKTI, might try to squeeze in NDRL list this year (+)
LKNCY: Luckin Coffee reported 50mn monthly transacting customers in June(/)


China TMT Update Jul.4-2252HK/1801HK/LEGN/LKNCY:14th Five-Year Plan for Medical Equipment Allocation

<ul>
<li>3690.HK/Douyin: Douyin's latest strategy in China food delivery market, per Chinese local media reports (-)</li>
<li>1024: Kuaishou launches annual eCommerce conference for merchants ( + )</li>
<li>LEGN：Legend raised another US$350mn, which can support at least one year of operation (+)</li>
</ul>


3690.HK/Douyin: Douyin's latest strategy in China food delivery market, per Chinese local media reports (-)
1024: Kuaishou launches annual eCommerce conference for merchants ( + )
LEGN：Legend raised another US$350mn, which can support at least one year of operation (+)


China TMT Update(May 10) - 3690.HK/Douyin/1024.HK/LEGN: Douyin's Latest Strategy in Food Delivery

China

Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Legend Biotech Corp (LEGN US)

APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...

Tina Banerjee

China TMT Update-NIO/BEKE/LEGN-NIO to Offer Single-Motor Model;Political Bureau Shifted Tone

NIO: NIO to offer single-motor model ;BEKE: Political Bureau of the Central Committee shifted tone on real estate regulation;LEGN: Janssen reported...

Blue Lotus Research Institute

Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio

1H26 results driven by AI orders; 2026 guidance upgrade on Life science and Probio; at US$7.2bn mkt cap (vs TWST: US$7.4bn), our quick back-of...

Wilfred Yuen

China TMT Update Jul.4-2252HK/1801HK/LEGN/LKNCY:14th Five-Year Plan for Medical Equipment Allocation

2252HK: "14th Five-Year Plan for Medical Equipment Allocation" , (-) 1801HK/LEGN: CAR-T received approval (+) LKNCY: Luckin Coffee reported 50mn...

Blue Lotus Research Institute

China TMT Update(May 10) - 3690.HK/Douyin/1024.HK/LEGN: Douyin's Latest Strategy in Food Delivery

Douyin/3690: Douyin's strategy in food delivery(-); 1024: Kuaishou launches annual eCommerce conference for merchants (+) ;LEGN：Legend raised...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)